KLOW Blend 80mg

Description

Product Specifications

• Product: KLOW Blend 80mg
• Compound / formulation: KLOW Blend
• Labeled blend composition: GHK-Cu 50mg + TB-500 (TB4) 10mg + BPC-157 10mg + KPV 10mg
• Labeled quantity / volume: 80mg total per vial
• Physical form: White lyophilized powder
• Research focus: Skin & Cellular Research, Extracellular Matrix Research, Tissue Repair Research, Inflammatory Signaling
• Available batch identifiers: Purple cap, batch KLOW-26-004
• SKU: HOP-klow-80mg
• Intended classification: Laboratory research only

Independent Laboratory Testing

Janoshik Analytical, report #235327 — Batch KLOW-26-004

• GHK-Cu measured content, sample A: 55.63mg
• GHK-Cu measured content, sample B: 55.70mg
• TB-500 (TB4) measured content, sample A: 11.91mg
• TB-500 (TB4) measured content, sample B: 12.05mg
• BPC-157 measured content, sample A: 11.41mg
• BPC-157 measured content, sample B: 11.57mg
• KPV measured content, sample A: 10.73mg
• KPV measured content, sample B: 10.79mg
• Combined measured content, sample A: 89.68mg
• Combined measured content, sample B: 90.11mg
• Test date: September 29, 2026
• View laboratory report
• View bacterial endotoxins report #235328

House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.

The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.

House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.

Scientific Research Background

KLOW combines four compounds studied in different areas of tissue and cellular biology.

GHK-Cu is a copper-binding peptide complex investigated for its relationship with collagen production, skin-related cellular activity, and the materials that give connective tissues their structure.

TB-500 (TB4) is the designation used in the product's analytical report. Published research involving Thymosin Beta-4 has examined cell movement, inflammatory responses, and tissue restoration. Without confirmation of the complete molecular sequence, findings involving full-length Thymosin Beta-4 cannot automatically be attributed to the TB-500 material in this blend.

BPC-157 is a synthetic peptide consisting of 15 amino acids. Laboratory and animal studies have examined its relationship with tendon structure, cellular responses following injury, and gastrointestinal tissues.

KPV is a short peptide consisting of three amino acids: lysine, proline, and valine. Researchers have investigated how it interacts with cells involved in inflammatory responses, particularly in experimental studies of intestinal tissue.

The individual compounds have different research histories. Their inclusion in one formulation does not establish how the complete four-component blend behaves.

Compound details

• Composition details: GHK-Cu is a copper-peptide complex; BPC-157 contains 15 amino acids; KPV contains three amino acids; TB-500 sequence not specified in the report
• Research classification: Multi-peptide tissue biology and inflammatory signaling research blend

Clinical Research Observations

Researchers have studied the individual peptides in KLOW Blend to better understand how tissues maintain their structure and respond to injury and inflammation. Most of these studies have involved laboratory experiments or animals rather than human clinical trials.

1. What have researchers learned about GHK-Cu and collagen?

Collagen contributes to the structure of skin and connective tissue.

What researchers found: In laboratory studies, researchers examined how GHK and its copper complex interact with cells responsible for producing collagen.

They observed changes in collagen production and the materials that help give skin and connective tissues their structure and flexibility.

Why it matters: These findings have contributed to scientific interest in how GHK-Cu interacts with the processes involved in maintaining skin and connective tissues. Laboratory collagen findings are not clinical proof of skin benefits.

2. What has thymosin beta-4 research examined?

Researchers investigate how cells help restore a tissue surface after injury.

What researchers found: In a study involving mice with experimentally injured corneas—the clear outer surface of the eye—researchers observed that tissues treated with Thymosin Beta-4 restored their protective surface more quickly than untreated tissues.

The researchers also reported fewer inflammatory cells in the affected area.

These observations have contributed to scientific interest in how Thymosin Beta-4 interacts with cells involved in tissue repair and maintenance.

Why it matters: Animal or cell repair findings cannot be generalized to human outcomes.

3. Why is BPC-157 studied in connective tissue?

Tendons connect muscles to bones. Their strength and organization are important in tissue research.

What researchers found: In a study involving rats with injured Achilles tendons, researchers observed differences in tendon strength, tissue organization, and movement compared with untreated animals.

The researchers also examined tendon-producing cells in laboratory experiments. They found that BPC-157 influenced how these cells responded to a substance that interferes with normal cell growth.

Why it matters: These findings contributed to scientific interest in how BPC-157 interacts with the tissues that connect muscles and bones. Tissue research in cells and animals does not establish healing in people.

4. What have KPV experiments found about inflammation?

Researchers study inflammation in intestinal cells and in animal models of digestive tissue.

What researchers found: In laboratory studies involving intestinal and immune cells, researchers observed that KPV reduced certain signals associated with inflammation.

Researchers also studied KPV in mice with experimentally induced intestinal inflammation. They observed lower levels of some inflammatory markers and less inflammation in the affected intestinal tissues.

Why it matters: These findings have contributed to scientific interest in how KPV interacts with cells involved in maintaining the protective lining of the digestive system. Inflammatory-marker changes in models do not establish clinical benefits.

5. What is known about the complete KLOW formulation?

Research on individual ingredients provides background, while the finished mixture needs its own investigation.

What researchers found: Researchers have studied GHK-Cu, TB-500, BPC-157, and KPV separately to understand their possible roles in tissue repair and inflammation.

KPV has also been studied for its effects on inflammation in the digestive system and the protective lining of the intestines.

These findings help explain why researchers are interested in the individual ingredients. However, studies of the separate ingredients do not tell us how they work together in KLOW or establish that the complete blend is safe or effective in humans.

The Thymosin Beta-4 findings also cannot automatically be attributed to the TB-500 material in this blend without confirming that the tested compounds have the same molecular structure.

Why it matters: The combined formulation has not been established as effective or safe in human trials.

Published Scientific Research

• Pickart, Vasquez-Soltero, and Margolina (2015) — GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. https://doi.org/10.1155/2015/648108 — A scientific review of GHK and GHK-Cu research involving collagen, skin-related cellular activity, and connective tissue organization.
• Sosne et al. (2002) — Thymosin Beta 4 Promotes Corneal Wound Healing and Decreases Inflammation In Vivo Following Alkali Injury. Experimental Eye Research. https://doi.org/10.1006/exer.2001.1125 — An animal study examining tissue restoration and inflammatory responses after experimental corneal injury.
• Staresinic et al. (2003) — Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and In Vitro Stimulates Tendocytes Growth. Journal of Orthopaedic Research. https://doi.org/10.1016/S0736-0266(03)00110-4 — An experimental study examining tendon structure, mechanical properties, and tendon-cell activity.
• Dalmasso et al. (2008) — PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. https://doi.org/10.1053/j.gastro.2007.10.026 — Laboratory and mouse research examining KPV's relationship with inflammatory responses in intestinal tissues.

Understanding the Research Findings

The published research discussed above involves individual compounds investigated under different experimental conditions. These studies provide information about collagen-related activity, tissue restoration, tendon biology, and inflammatory responses.

They do not establish how the exact KLOW Blend formulation behaves or whether combining its four components produces additive or synergistic effects.

The distinction between TB-500 and full-length Thymosin Beta-4 is particularly important. The laboratory report uses the designation TB-500 (TB4) without specifying a complete peptide sequence. Findings involving Thymosin Beta-4 should therefore be understood as related scientific background rather than direct confirmation of the biological activity of the TB-500 component.

Independent laboratory testing provides information about the identity and measured quantities of the submitted blend samples and a separately reported endotoxin result. These analytical findings do not establish clinical effectiveness, safety, or equivalence to materials evaluated in published studies.

House of Peptides' research product is not FDA-approved or represented as clinically equivalent to pharmaceutical or experimental materials used in clinical investigations.

Research Use Notice

For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.